Ruc pkpd
Indication: BRCA-mutant and HRD+ breast cancer
Semi-mechanistic PK/PD model for rucaparib (PARP inhibitor) with DDR-based tumor growth inhibition. Two-compartment clinical PK with Gompertz TGI model showing synthetic lethality in BRCA-mutant and HRD+ tumors. Based on Villette et al. (2025) Br J Cancer.
Drug Overview
Clinical Context
- Molecular Target
- PARP (poly ADP-ribose polymerase)
- Drug Class
- PARP inhibitor
- Therapeutic Area
- Oncology
- Indication
- BRCA-mutant and HRD+ breast cancer
- Route of Administration
- Oral
Model Information
- Model Type
- Semi-mechanistic PK/PD
- Reference
- Villette et al. (2025) Br J Cancer
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| CL F | clinical PK (2-compartment oral) |
| t half | ~17 h |
Additional Parameters
| Parameter | Value |
|---|---|
| PD model | Gompertz tumor growth inhibition with DDR-based synthetic lethality |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Ruc allows you to explore concentration-time profiles under different dosing scenarios. The underlying Semi-mechanistic PK/PD model characterizes the pharmacokinetics of this parp inhibitor following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Ruc PK simulator?
This is a free, interactive pharmacokinetic simulator for Ruc used in BRCA-mutant and HRD+ breast cancer. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Ruc belong to?
Ruc is classified as a PARP inhibitor that targets PARP (poly ADP-ribose polymerase). It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Ruc. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Semi-mechanistic PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of Ruc?
Based on the published model parameters, the elimination half-life of Ruc is approximately ~17 h. Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of Ruc?
The clearance (CL) of Ruc is approximately clinical PK (2-compartment oral). Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Related Simulators
PopPK of Docetaxel
capecitabine
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Ready to Simulate?
Launch the Ruc simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community